Jafri Nazia F, Ma Patrick C, Maulik Gautam, Salgia Ravi
Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
J Environ Pathol Toxicol Oncol. 2003;22(3):147-65. doi: 10.1615/jenvpathtoxoncol.v22.i3.10.
Small-cell lung cancer (SCLC) is an aggressive, malignant neoplasm with a 5-year survival of less than 10%. This poor survival rate is related to a high propensity for recurrence and a high rate of metastases. Metastases initially occur in the lymph nodes and thereafter in other organs such as the lung itself, liver, adrenal glands, brain, bone, and bone marrow. The mechanisms of metastases have been better understood recently and are described in this review. Receptor tyrosine kinases (RTKs) have been identified as important therapeutic targets in non-small-cell lung cancer (such as the EGF-receptor). We have begun to identify RTKs in SCLC and have shown that c-Kit and c-Met are expressed and functional in SCLC. RTKs have also been shown to be important in the metastasis of cancer cells. The roles of RTKs in the mechanism of metastasis are detailed in this review, with special emphasis on downstream signal transduction from RTK signaling.
小细胞肺癌（SCLC）是一种侵袭性恶性肿瘤，5年生存率低于10%。这种低生存率与高复发倾向和高转移率有关。转移最初发生在淋巴结，随后发生在其他器官，如肺本身、肝脏、肾上腺、脑、骨和骨髓。转移机制最近已得到更好的理解，并在本综述中进行了描述。受体酪氨酸激酶（RTK）已被确定为非小细胞肺癌的重要治疗靶点（如表皮生长因子受体）。我们已开始在小细胞肺癌中鉴定RTK，并已表明c-Kit和c-Met在小细胞肺癌中表达且具有功能。RTK在癌细胞转移中也已被证明很重要。本综述详细阐述了RTK在转移机制中的作用，特别强调了RTK信号传导的下游信号转导。
